W
Wilson Therapeutics
Developing novel treatments for Wilson Disease
About Wilson Therapeutics
Wilson Therapeutics, now part of Alexion Pharmaceuticals, is a biopharmaceutical company dedicated to developing transformative therapies for individuals suffering from rare and severe diseases. The company primarily serves patients with limited treatment options, focusing on conditions that are often overlooked by larger pharmaceutical firms. Operating within the niche market of rare diseases, Wilson Therapeutics employs a business model centered around research and development, clinical trials, and strategic partnerships. Revenue is generated through the commercialization of its proprietary therapies, often in collaboration with third-party companies in select countries to manage local commercial operations. By addressing unmet medical needs, Wilson Therapeutics aims to create significant value for patients and their families, ultimately improving their quality of life.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1984
- Headquarters
- Stockholm, Sweden
- Listing
- IPO 2016
- Employees
- 702
- Open positions
- None listed
- Dealroom signal
- 83.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- B2B, B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Apr 2018 | $855M | $855M | Alexion Pharmaceuticals | — |
| POST IPO EQUITY✓Other financing | Dec 2017 | $30M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Wilson Therapeutics is 0 monthly website visits. Wilson Therapeutics's team grew 83.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Wilson Therapeutics in the Stockholm ecosystem
The Wilson Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Abingworth
MVM Life Science Partners
NeoMed
HealthCap
Other known investors1 additional known investor
Alexion Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Wilson Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Wilson Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










